Why Is Mesalamine XR So Hard to Find? [Explained for 2026]

You went to pick up your Mesalamine XR prescription and your pharmacy said they're out of stock — or maybe they don't know when it's coming back. If that sounds familiar, you're not alone. Patients across the United States are reporting difficulty finding Mesalamine extended-release capsules (Pentasa, Apriso, and generics) in 2026, and the frustration is real.

For people managing ulcerative colitis, running out of a maintenance medication isn't just inconvenient — it can trigger a flare that sets back months of progress. In this article, we'll break down exactly why Mesalamine XR can be so difficult to find and what you can do about it right now.

Is There an Official Mesalamine XR Shortage in 2026?

Yes — in part. As of March 2026, the American Society of Health-System Pharmacists (ASHP) has confirmed that Sun Pharmaceutical Industries' mesalamine extended-release 500 mg capsules (120-count bottles) are on back order with no estimated resupply date. This is the same formulation sold as the generic version of Pentasa, the widely prescribed extended-release capsule.

At the same time, the brand-name Apriso (mesalamine 0.375 g extended-release capsules) is not on the FDA's official drug shortage list as of early 2026. However, patients still report trouble filling Apriso prescriptions at their local pharmacies. This gap between official listings and real-world availability is a common frustration with specialty maintenance medications.

Why Is Mesalamine XR So Difficult to Manufacture?

Mesalamine XR is what's called a "difficult to make" product — a term used by pharmaceutical companies themselves. In 2025, Amneal Pharmaceuticals specifically noted that mesalamine is a complex product with a limited number of suppliers when they launched their own delayed-release version.

The extended-release formulation is especially challenging because the capsules rely on precise polymer coatings (ethylcellulose granules) that control how and where the drug releases along the GI tract. Manufacturing these coatings consistently requires specialized equipment and tight quality control. When something goes wrong at one facility, the entire supply chain feels it.

What's Driving the Mesalamine XR Supply Problems Right Now?

Several factors combine to make Mesalamine XR harder to find than many other medications:

Active manufacturer back order: Sun Pharma's 500 mg ER capsules have no estimated return date as of March 2026, reducing the supply of a major generic option.

Few generic manufacturers: Even though generic Mesalamine XR is available from multiple companies, the list of manufacturers producing the 500 mg ER capsule is small. A single back order can create widespread gaps.

Pharmacy stocking decisions: Chain pharmacies use automated inventory systems based on recent dispensing volume. Low-volume specialty medications like Mesalamine XR are often stocked in small quantities, meaning a few patients filling prescriptions at the same time can exhaust local supply.

Generic substitution shifts: Since generic Mesalamine ER became widely available, many pharmacies dropped brand-name Apriso from their inventory. If your prescription calls for a specific brand or strength, your pharmacy may simply not carry it anymore.

Regional distribution gaps: Even when national supply is adequate, wholesale distribution patterns can create pockets of unavailability in specific regions.

How Many People Are Affected by This Shortage?

Approximately 600,000 to 900,000 people in the United States are living with ulcerative colitis, and many of them rely on mesalamine as a long-term maintenance medication. Because this is a chronic condition requiring consistent dosing, even a short supply disruption can have real consequences for patients' health.

Annual U.S. sales of mesalamine formulations run into the hundreds of millions of dollars — with mesalamine 800 mg alone generating approximately $147 million in the 12 months ending December 2024 according to IQVIA data. Pentasa ER capsules had annual sales of approximately $213 million based on March 2022 IQVIA data. This is not a niche drug — it's a cornerstone treatment for hundreds of thousands of Americans.

What Happens If You Miss Doses of Mesalamine XR?

Mesalamine XR is a maintenance medication, meaning it works best when taken consistently over time to prevent colitis flares. Missing a few doses doesn't guarantee a flare, but the risk increases — especially in patients who have been in remission and may not notice early warning signs.

If you've missed doses because you can't find your medication, contact your doctor as soon as possible. They may be able to call ahead to specific pharmacies, provide samples, prescribe a related formulation, or help bridge the gap with a different treatment until supply normalizes.

What Can You Do Right Now to Find Mesalamine XR?

Here are the most effective steps you can take today:

Use medfinder: Visit medfinder.com — tell us your medication, dosage, and location and we'll call pharmacies near you to find out who has Mesalamine XR in stock. This saves you hours of calling around yourself.

Try independent pharmacies: Independent pharmacies often have more flexibility to source medications quickly and can special-order within 1–2 business days. Don't limit your search to large chain pharmacies.

Check mail-order pharmacies: Services like Express Scripts, CVS Caremark, and Amazon Pharmacy often have more reliable stock for maintenance medications and may be able to ship within a few days.

Ask about the 0.375 g capsule (Apriso): If your pharmacy is out of the 500 mg capsules, the Apriso-strength (0.375 g) generic may be available. Talk to your doctor first — the dosing schedule is different.

Ask about alternatives: Other mesalamine formulations (Lialda, Delzicol) or related medications (balsalazide, sulfasalazine) may be available and appropriate. Read more in our guide: Alternatives to Mesalamine XR if you can't fill your prescription.

Will the Mesalamine XR Shortage Get Better in 2026?

The mesalamine ER market is mature, with multiple manufacturers approved to produce generic versions. The current ASHP-listed shortage is specific to Sun Pharma's 500 mg capsule back order. Other manufacturers continue to supply the market, and Apriso (0.375 g) is not in formal shortage.

That said, even without a formal nationwide shortage, localized pharmacy availability issues can persist for months. The best strategy is to be proactive: don't wait until your last dose to look for refills, and keep your doctor informed about any access problems.

The Bottom Line

Mesalamine XR can be hard to find in 2026 due to an active ASHP back order on Sun Pharma's 500 mg capsules, complex manufacturing challenges, limited pharmacy stocking, and regional distribution gaps. But supply does exist — it just takes more effort to locate. medfinder is designed to do that work for you. For the latest on the shortage, see our Mesalamine XR shortage update for 2026.